Mounjaro: What is the ‘golden dose’ and what are the risks?
Post Content
Head of addiction medicine society warns of treatment cuts and rising threat of gambling
BOSTON — The president of a leading addiction medicine group issued stark warnings on hardline Trump administration policies on substance use, low rates of addiction treatment uptake, and a rise in problem gambling. But Stephen Taylor, the president of the American Society of Addiction Medicine, tempered his remarks with optimism. In particular, he expressed hope […]
Novo GLP-1 pill OK’d in U.S. for heart disease risk (NVO:NYSE) – Seeking Alpha
Novo GLP-1 pill OK’d in U.S. for heart disease risk (NVO:NYSE) Seeking Alpha FDA Approves Novo Nordisk’s Rybelsus Diabetes Pill to Reduce Heart Risk The Wall Street Journal First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved New Atlas FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type […]
How big is the GLP-1 wave going to get, really?
GLP-1 drugs like Ozempic and Wegovy are transforming public health and consumer habits. Here we explore their explosive growth, future potential, and impact on the food industry.
BF Biosciences brings GLP-1 manufacturing to Pakistan
BF Biosciences Ltd has begun local manufacturing of tirzepatide, bringing one of the world’s most sought-after metabolic drugs into production on Pakistani soil. In a material disclosure to the Pakistan Stock Exchange, the company said it has launched Zeptide (tirzepatide) in an easy-to-use pre-filled syringe, produced at its new European-specification pre-filled syringes facility. The company […]
FDA Approves Rybelsus (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes Who Are at High Risk
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 17, 2025 /PRNewswire/ — Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major…
First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk’s once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke. Continue Reading Category: Diabetes, Illnesses and conditions, Body and Mind Tags: Novo Nordisk, Heart Disease, Cardiovascular […]
Lilly’s oral GLP-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials, Reconfirming Its Potential as a Foundational Treatment in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron…
Doctors Just Found Something Fascinating About What Happens When You Drink on Ozempic
GLP-1 drugs like semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, were originally intended to treat diabetes — and didn’t become blockbuster prescriptions until doctors realized that they were also potent weight loss aids that seem to re-wire patients’ relationship to food and satiety. Since then, it’s slowly been emerging that they have […]
Fight Aging! Newsletter, October 20th 2025
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe to the newsletter, please visit: https://www.fightaging.org/newsletter/. To unsubscribe, send email or reply to […]